AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Immunovia Names Natalie Carfora VP of Market Access and Reimbursement Ahead of PancreaSure Launch
ByAinvest
Monday, Jul 21, 2025 3:18 am ET1min read
Immunovia has appointed Natalie Carfora as Vice President of Market Access and Reimbursement to secure coverage and reimbursement for its new PancreaSure test in the US. Carfora returns to Immunovia after a stint at Lucid Diagnostics, where she secured the first positive policy decision for an esophageal DNA test and worked on Medicare coverage initiatives. Her role is critical to Immunovia's business, with a proven track record of success.
Lund, Sweden – Immunovia (publ.) has appointed Natalie Carfora as Vice President, Market Access and Reimbursement, a critical role aimed at securing U.S. coverage and reimbursement for the company's PancreaSure test. Carfora returns to Immunovia after leading market access at Lucid Diagnostics, where she secured the first positive policy decision for an esophageal DNA test and successfully guided Medicare coverage reconsideration [2].Jeff Borcherding, CEO of Immunovia, highlighted the significance of Carfora's appointment: "This recruitment is business-critical for us. Natalie brings exceptional expertise, deep familiarity with Immunovia, and a proven track record of success," he said [1].
Carfora's extensive experience in market access and sales in medical diagnostics will be instrumental in navigating the reimbursement process for PancreaSure. She has a history of engaging with commercial and governmental payors on coverage policy and has led market access initiatives, including clinical study design collaboration and payor pilot programs [2].
The appointment comes as Immunovia prepares to launch the PancreaSure test, which aims to detect pancreatic cancer at an early stage. The U.S. market is critical for Immunovia, with an estimated 1,8 million individuals who could benefit from the test annually [1].
Carfora expressed enthusiasm about her return to Immunovia: "I'm excited to return at a time when there's real momentum building here. As the launch of the PancreaSure test approaches and the reimbursement process moves forward, my experiences will help us navigate with speed and purpose," she said [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025-07-21:newsml_MFN9kC9F2:0-immunovia-appoints-natalie-carfora-as-vp-market-access-and-reimbursement/
[2] https://mfn.se/a/immunovia/immunovia-utser-natalie-carfora-till-vp-market-access-and-reimbursement
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet